A Systematic Review: Comparison of triple drug therapy versus double drug therapy for Lymphatic Filariasis
Article Sidebar
Main Article Content
Abstract
Background: Lymphatic filariasis is a parasitic infection caused by nematodes such as filaria Wuchereria bancrofti, Brugia malayi, and Brugia timori. These parasites can be transmitted through mosquito bites such as several species of mosquitoes, particularly Anopheles, Aedes, Culex, and Mansonia with geographical variations in the dominant vector identity. The main strategy used consists of community-wide mass drug administration (MDA) for the entire population at risk to stop disease transmission and prevent infectious morbidity. WHO recommends the use of annual medication in combination with the triple drug ivermectin therapy.
Objective: To compare DEC and albendazole (IDA) versus the two drugs albendazole and diethycarbamazine or albendazole and ivermectin therapy.
Methods: The literature search was carried out independently by the researcher using the Sciencedirect, Pubmed, and Cochrane online databases without limiting the type of study or the year of publication. The keywords used in this study were combined with the Boolean operator, namely "AND" namely ((((Lymphatic filariasis) AND (albendazole)) AND (diethylcarbamazine)) AND (ivermectin)) AND (compare).
Results: Where triple drug therapy was significantly better in reducing and clearing microfilariae and worm nests in patients with lymphatic filariasis compared to two drug therapy alone. However, side effects occur more frequently in the combination of three therapies. The average side effects were low, such as headaches, joint pain, fatigue, and nausea.
Conclusion: although it has relatively low side effects that occur in three drug combinations rather than two drug combination therapy, triple therapy combination therapy is more effective than two drug therapy in treating lymphatic filariasis disease.
Downloads
Article Details
Copyright (c) 2021 I Gusti Agung Ari Kusuma Yana
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
World Health Organization. Global programme to eliminate lymphatic filariasis: progress report, 2015. 2016;(7):73–88. Available from: http://www.who.int/wer
Rahman MA, Yahathugoda TC, Tojo B, Premaratne P, Nagaoka F, Takagi H, et al. A surveillance system for lymphatic filariasis after its elimination in Sri Lanka. Parasitol Int [Internet]. 2019;68(1):73–8. Available from: https://doi.org/10.1016/ j.parint.2018.10.003
Deshpande A, Miller-Petrie MK, Lindstedt PA, Baumann MM, Johnson KB, Blacker BF, et al. The global distribution of lymphatic filariasis, 2000–18: a geospatial analysis. Lancet Glob Heal. 2020;8(9):e1186–94.
Koudou BG, de Souza DK, Biritwum NK, Bougma R, Aboulaye M, Elhassan E, et al. Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary? Lancet Infect Dis [Internet]. 2018;18(6):e214–20. Available from: http://dx.doi.org/10.1016/S1473-3099(18)30069-0
Ottesen EA. Lymphatic Filariasis: Treatment, Control and Elimination. Adv Parasitol. 2006;61(05):395–441.
Cl M, Ss B, Johnson S, Richardson M, Garner P. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis ( Review ) SUMMARY OF FINDINGS FOR THE MAIN COMPARISON. 2019;(1).
Kulkarni P, Thomas JJ, Dowerah J, Narayana Murthy MR, Ravikumar K. Mass drug administration programme against lymphatic filariasis-an evaluation of coverage and compliance in a northern Karnataka district, India. Clin Epidemiol Glob Heal [Internet]. 2020;8(1):87–90. Available from: https://doi.org/10.1016/ j.cegh.2019.04.013
Lourens GB, Ferrell DK. Lymphatic Filariasis. Nurs Clin North Am [Internet]. 2019;54(2):181–92. Available from: https://doi.org/10.1016/j.cnur.2019.02.007
Oluwabiyi B, Oyeyemi OT, Olorunlana A, Omiyeniyi N, Koleosho A. Lymphatic Filariasis in Southwestern Nigerian Rural Communities: A Cross-sectional Survey of the Knowledge, Awareness, and Predisposing Factors. Ann Glob Heal. 2016;82(5):806–12.
World Health Organization. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis [Internet]. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. 2017. 1–71 p. Available from:http://www.ncbi.nlm.nih.gov/pubmed/295655 23
Irvine MA, Stolk WA, Smith ME, Subramanian S, Singh BK, Weil GJ, et al. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study. Lancet Infect Dis [Internet]. 2017;17(4):451–8. Available from:http://dx.doi.org/10.1016/S1473-3099(16)30467-4
Bockarie MJ, Pedersen EM, White GB, Michael E. Role of vector control in the global program to eliminate lymphatic filariasis. Annu Rev Entomol. 2009;54:469–87.
CDC. The Life Cycle of Lymphatic Filariasis [Internet]. Global Health, Division of Parasitic Diseases and Malaria. 2018 [cited 2020 Oct 6]. p. 8. Available from:https://www.carter
center.org/resources/pdfs/health/lf/lymphaticfilariasis-life-cycle
Shenoy RK, Bockarie MJ. Lymphatic filariasis in children: Clinical features, infection burdens and future prospects for elimination. Parasitology. 2011;138 (12):1559–68.
Davis EL, Reimer LJ, Pellis L, Hollingsworth TD. Evaluating the Evidence for Lymphatic Filariasis Elimination. Trends Parasitol [Internet]. 2019;35(11):860–9. Available from:https://doi.org/10.1016/j.pt.2019.08.003
Pfarr KM, Debrah AY, Specht S, Hoerauf A. Filariasis and lymphoedema. Parasite Immunol. 2009;31(11):664–72.
Babu S, Nutman TB. Immunology of lymphatic filariasis. Parasite Immunol. 2014;36(8):338–46.
KANAAN AL-TAMEEMI, RAIAAN KABAKLI. Lymphatic Filariasis: an Overview. Asian J Pharm Clin Res. 2019;12(12):1–5.
Jones C, Ngasalla B, Derua YA, Tarimo D, Malecela MN. Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets. Int J Infect Dis [Internet]. 2017;61:38–43. Available from:http://dx.doi.org/10.1016/j.ijid.2017.05.009
Bal M, Ranjit M, Achary KG, Satapathy AK. Maternal Filarial Infection Influences the Development of Regulatory T Cells in Children from Infancy to Early Childhood. PLoS Negl Trop Dis. 2016;10(11):1–15.
Bal M, Ranjit M, Satapathy AK, Khuntia HK, Pati S. Filarial infection during pregnancy has profound consequences on immune response and disease outcome in children: A birth cohort study. PLoS Negl Trop Dis. 2018;12(9):1–16.
Knoll BM, Mylonakis E, Division ID, Hospital RI, Medical WA. Familial aggregation and heritability of Wuchereria bancrofti infection. 2013;1–19.
Al-Kubati AS, Al-Samie AR, Al-Kubati S, Ramzy RMR. The story of Lymphatic Filariasis elimination as a public health problem from Yemen. Acta Trop [Internet]. 2020;212(June):105676. Available from: https://doi.org/10.1016/j.actatropica.2020.105676
Komoreng L, Thekisoe O, Lehasa S, Tiwani T, Mzizi N, Mokoena N, et al. An ethnobotanical survey of traditional medicinal plants used against lymphatic filariasis in South Africa. South African J Bot [Internet]. 2017;111:12–6. Available from: http://dx.doi.org/10.1016j.sajb.2017.03.005
Kamgno J, Djeunga HN. Progress towards global elimination of lymphatic filariasis. Lancet Glob Heal [Internet]. 2020;8(9):e1108–9. Available from: http://dx.doi.org/10.1016/S2214-
X(20)30323-5
Kouassi BL, Barry A, Heitz-Tokpa K, Krauth SJ, Goépogui A, Baldé MS, et al. Perceptions, knowledge, attitudes and practices for the prevention and control of lymphatic filariasis in Conakry, Republic of Guinea. Acta Trop [Internet]. 2018;179:109– 16. Available from:http://dx.doi.org/10.1016/j.actatropica.2017.12.002
Organization WH. WORLD HEALTH ORGANIZATION GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS [Internet]. 2013. Available from: (www. who.int)
Amaechi EC, Ohaeri CC, Ukpai OM, Nwachukwu PC, Ukoha UK. Lymphatic filariasis: knowledge, attitude and practices among inhabitants of an irrigation project community, North Central Nigeria. Asian Pacific J Trop Dis [Internet]. 2016;6(9):709–13. Available from:
http://dx.doi.org/10.1016/S2222-1808(16)61114-3
Professor Onyebuchi C.O.Chukwu. Nigeria Launches Africa ’ s First Nationwide Malaria and Lymphatic Filariasis (Elephantiasis) Elimination Co-Implementation Plan For Immediate Release DATE: Wednesday 19. Honour Minist Heal. 2014;
Nsakashalo-Senkwe M, Mwase E, ChizemaKawesha E, Mukonka V, Songolo P, Masaninga F, et al. Significant decline in lymphatic filariasis associated with nationwide scale-up of insecticide-treated nets in Zambia. Parasite Epidemiol Control [Internet]. 2017;2(4):7–14. Available from:
http://dx.doi.org/10.1016/j.parepi.2017.08.001
Horstick O, Runge-Ranzinger S. Protection of the house against Chagas disease, dengue, leishmaniasis, and lymphatic filariasis: a systematic review. Lancet Infect Dis [Internet]. 2018;18(5):e147–58. Available from: http://dx.doi.org/10.1016/S1473-3099(17)30422-X
Netto MJ, Bonfim C, Brandão E, AguiarSantos AM, Medeiros Z. Burden of lymphatic filariasis morbidity in an area of low endemicity in Brazil. Acta Trop [Internet]. 2016;163:54–60. Available from: http://dx.doi.org/10.1016/j.actatropica.2016.07.006
Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis. 2016;62(3):334–41.
King CL, Suamani J, Sanuku N, Cheng YC, Satofan S, Mancuso B, et al. A trial of a triple-drug treatment for lymphatic filariasis. N Engl J Med. 2018;379(19):1801–10.
Bjerum CM, Ouattara AF, Aboulaye M, Kouadio O, Marius VK, Andersen BJ, et al. Efficacy and Safety of a Single Dose of Ivermectin, Diethylcarbamazine, and Albendazole for Treatment of Lymphatic Filariasis in Côte d’Ivoire: An Open-label Randomized Controlled Trial. Clin Infect Dis. 2019;(Xx Xxxx):1–8.
Dubray CL, Sircar AD, de Rochars VMB, Bogus J, Direny AN, Ernest JR, et al. Safety and efficacy of co-administered diethylcarbamazine, albendazole and ivermectin during mass drug administration for lymphatic filariasis in Haiti: Results from a two-armed, open-label, cluster-randomized, community study. PLoS Negl Trop Dis [Internet]. 2020;14(6):1–21. Available from: